AVTX
Avalo Therapeutics, Inc.$15.87-0.33 (-2.01%)Prev Close$16.18·MCap$1.04B·P/E—·Vol746.3K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
24
$8.03M
◆
Net Activity
Net Seller
$8.03M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Avalo Therapeutics, Inc. (AVTX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 24 insider sales totaling $8.03M. The most recent insider transaction was by Sullivan Christopher Ryan (officer: Chief Financial Officer), who sold $179.5K worth of shares on Sep 11, 2026. Avalo Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.04B.
AVTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 10,185 | $17.62 | $179.5K | 39,900 |
| Sep 1, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 679 | $20.00 | $13.6K | 51,776 |
| Aug 19, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 1,000 | $20.00 | $20.0K | 51,776 |
| Aug 19, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 72,725 | $19.94 | $1.45M | 43,649-62% |
| Aug 12, 2026 | Riley Jennifer | officer: Chief Strategy Officer | Sell | 2,655 | $19.59 | $52.0K | 37,041 |
| Aug 12, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 679 | $20.00 | $13.6K | 51,776 |
| Jul 29, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 1,000 | $20.00 | $20.0K | 51,776 |
| Jul 2, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 4,654 | $20.00 | $93.1K | 51,776 |
| Jun 25, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 1,450 | $18.00 | $26.1K | 51,776 |
| Jun 1, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 679 | $16.00 | $10.9K | 47,122 |
| May 19, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 3,000 | $18.76 | $56.3K | 3,622-45% |
| May 11, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 18,606 | $24.12 | $448.8K | 423-98% |
| May 7, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 47,000 | $20.19 | $948.7K | 33,589-58% |
| May 7, 2026 | Chan Mitchell | director | Sell | 3,167 | $22.88 | $72.5K | 3,166-50% |
| May 7, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 108,234 | $20.61 | $2.23M1.0% OS | 82,639-57% |
| May 7, 2026 | VARKI PAUL | officer: Chief Legal Officer | Sell | 75,063 | $20.17 | $1.51M0.7% OS | 41,322-64% |
| May 1, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 16,915 | $13.16 | $222.6K | 8,880-66% |
| Apr 8, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 3,970 | $18.01 | $71.5K | 3,622-52% |
| Mar 18, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 25,492 | $16.15 | $411.6K | 3,622-88% |
| Dec 10, 2025 | Doyle Mittie | Chief Medical Officer | Sell | 1,013 | $4.10 | $4.2K | 0 |
| Dec 10, 2025 | Riley Jennifer | Chief Strategy Officer | Sell | 637 | $4.10 | $2.6K | 0 |
| Dec 10, 2025 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 155 | $4.10 | $635.50 | 0 |
| Dec 10, 2025 | VARKI PAUL | Chief Legal Officer | Sell | 1,016 | $4.10 | $4.2K | 0 |
| Nov 14, 2025 | Goldman Jonathan | Director | Sell | 11,367 | $14.33 | $162.9K | 0 |
| Mar 28, 2025 | NEIL GARRY ARTHUR | Chief Executive Officer | Sell | 17,787 | $8.46 | $150.5K | 0 |
| Mar 28, 2025 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 7,285 | $8.46 | $61.6K | 0 |
| Nov 12, 2024 | Almenoff June Sherie | Director | Buy | 1,000 | $12.75 | $12.7K | 0 |
| Jun 9, 2023 | NEIL GARRY ARTHUR | CEO and Chairman of the Board | Buy | 4,000 | $3.42 | $13.7K | 0 |
| Jun 9, 2023 | Sullivan Christopher Ryan | Chief Financial Officer | Buy | 511 | $3.42 | $1.7K | 0 |
| Dec 9, 2022 | NEIL GARRY ARTHUR | CEO and Chairman of the Board | Buy | 2,083 | $4.42 | $9.2K | 0 |
| Dec 10, 2021 | Greenway Schond L. | CFO | Buy | 2,231 | $1.57 | $3.5K | 0 |
| Dec 10, 2021 | Harrell James Archie Jr | Chief Commercial Officer | Buy | 1,093 | $1.57 | $1.7K | 0 |
| Dec 10, 2021 | NEIL GARRY ARTHUR | Chief Scientific Officer | Buy | 4,267 | $1.57 | $6.7K | 0 |
| Dec 10, 2021 | Sullivan Christopher Ryan | Chief Accounting Officer | Buy | 955 | $1.57 | $1.5K | 0 |
| Dec 10, 2021 | Wilkins H Jeffrey | Chief Medical Officer | Buy | 6,371 | $1.57 | $10.0K | 0 |
| Jun 10, 2021 | Greenway Schond L. | CFO | Buy | 652 | $2.68 | $1.7K | 0 |
| Jun 10, 2021 | Harrell James Archie Jr | Chief Commercial Officer | Buy | 7,493 | $2.28 | $17.1K | 0 |
| Jun 10, 2021 | NEIL GARRY ARTHUR | Chief Scientific Officer | Buy | 3,692 | $2.28 | $8.4K | 0 |
| Jun 10, 2021 | Wilkins H Jeffrey | Chief Medical Officer | Buy | 912 | $2.28 | $2.1K | 0 |
AVTX Insider Buying Activity
The following table shows recent insider purchases of Avalo Therapeutics, Inc. (AVTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | Almenoff June Sherie | Director | Buy | 1,000 | $12.75 | $12.7K | 0 |
| Jun 9, 2023 | NEIL GARRY ARTHUR | CEO and Chairman of the Board | Buy | 4,000 | $3.42 | $13.7K | 0 |
| Jun 9, 2023 | Sullivan Christopher Ryan | Chief Financial Officer | Buy | 511 | $3.42 | $1.7K | 0 |
| Dec 9, 2022 | NEIL GARRY ARTHUR | CEO and Chairman of the Board | Buy | 2,083 | $4.42 | $9.2K | 0 |
| Dec 10, 2021 | Greenway Schond L. | CFO | Buy | 2,231 | $1.57 | $3.5K | 0 |
| Dec 10, 2021 | Harrell James Archie Jr | Chief Commercial Officer | Buy | 1,093 | $1.57 | $1.7K | 0 |
| Dec 10, 2021 | NEIL GARRY ARTHUR | Chief Scientific Officer | Buy | 4,267 | $1.57 | $6.7K | 0 |
| Dec 10, 2021 | Sullivan Christopher Ryan | Chief Accounting Officer | Buy | 955 | $1.57 | $1.5K | 0 |
| Dec 10, 2021 | Wilkins H Jeffrey | Chief Medical Officer | Buy | 6,371 | $1.57 | $10.0K | 0 |
| Jun 10, 2021 | Greenway Schond L. | CFO | Buy | 652 | $2.68 | $1.7K | 0 |
| Jun 10, 2021 | Harrell James Archie Jr | Chief Commercial Officer | Buy | 7,493 | $2.28 | $17.1K | 0 |
| Jun 10, 2021 | NEIL GARRY ARTHUR | Chief Scientific Officer | Buy | 3,692 | $2.28 | $8.4K | 0 |
| Jun 10, 2021 | Wilkins H Jeffrey | Chief Medical Officer | Buy | 912 | $2.28 | $2.1K | 0 |
AVTX Insider Selling Activity
The following table shows recent insider sales of Avalo Therapeutics, Inc. (AVTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 10,185 | $17.62 | $179.5K | 39,900 |
| Sep 1, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 679 | $20.00 | $13.6K | 51,776 |
| Aug 19, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 1,000 | $20.00 | $20.0K | 51,776 |
| Aug 19, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 72,725 | $19.94 | $1.45M | 43,649-62% |
| Aug 12, 2026 | Riley Jennifer | officer: Chief Strategy Officer | Sell | 2,655 | $19.59 | $52.0K | 37,041 |
| Aug 12, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 679 | $20.00 | $13.6K | 51,776 |
| Jul 29, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 1,000 | $20.00 | $20.0K | 51,776 |
| Jul 2, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 4,654 | $20.00 | $93.1K | 51,776 |
| Jun 25, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 1,450 | $18.00 | $26.1K | 51,776 |
| Jun 1, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 679 | $16.00 | $10.9K | 47,122 |
| May 19, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 3,000 | $18.76 | $56.3K | 3,622-45% |
| May 11, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 18,606 | $24.12 | $448.8K | 423-98% |
| May 7, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 47,000 | $20.19 | $948.7K | 33,589-58% |
| May 7, 2026 | Chan Mitchell | director | Sell | 3,167 | $22.88 | $72.5K | 3,166-50% |
| May 7, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 108,234 | $20.61 | $2.23M1.0% OS | 82,639-57% |
| May 7, 2026 | VARKI PAUL | officer: Chief Legal Officer | Sell | 75,063 | $20.17 | $1.51M0.7% OS | 41,322-64% |
| May 1, 2026 | Sullivan Christopher Ryan | officer: Chief Financial Officer | Sell | 16,915 | $13.16 | $222.6K | 8,880-66% |
| Apr 8, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 3,970 | $18.01 | $71.5K | 3,622-52% |
| Mar 18, 2026 | Doyle Mittie | officer: Chief Medical Officer | Sell | 25,492 | $16.15 | $411.6K | 3,622-88% |
| Dec 10, 2025 | Doyle Mittie | Chief Medical Officer | Sell | 1,013 | $4.10 | $4.2K | 0 |
| Dec 10, 2025 | Riley Jennifer | Chief Strategy Officer | Sell | 637 | $4.10 | $2.6K | 0 |
| Dec 10, 2025 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 155 | $4.10 | $635.50 | 0 |
| Dec 10, 2025 | VARKI PAUL | Chief Legal Officer | Sell | 1,016 | $4.10 | $4.2K | 0 |
| Nov 14, 2025 | Goldman Jonathan | Director | Sell | 11,367 | $14.33 | $162.9K | 0 |
| Mar 28, 2025 | NEIL GARRY ARTHUR | Chief Executive Officer | Sell | 17,787 | $8.46 | $150.5K | 0 |
| Mar 28, 2025 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 7,285 | $8.46 | $61.6K | 0 |
AVTX Insiders
Sullivan Christopher Ryan
officer: Chief Financial Officer
Bought $3.2KSold $3.31M
9 tradesLast: Sep 11, 2026
Similar Stocks to AVTX
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B